Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study (VOG-HD)

September 29, 2015 updated by: University Hospital, Angers
The purpose of this study is to know the limits of feasibility of a reliable oculomotor record for patient with Huntington's disease.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Corrected visual acuity >1/10
  • Aged over 18 years
  • Patient with the mutation that is to say the presence of an abnormal number of trinuclide: CAG> 38 in the first exon of the huntingtin gene.
  • Total Functional Capacity Scale (CFT) ≥ 3

Exclusion Criteria:

  • Patients or trustworthy person who have not given their written consent, informed and signed.
  • Patients are not affiliated or who are not entitled to Social Security
  • Private patients of liberty by administrative or judicial decision, or patients supervision
  • Associated disease with neurological repercussions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patient with Huntington's disease
Device: Eye-tracking

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
saccadic measures with the eye tracker
Time Frame: 1 day
one measure in the evening and one in the afternoon
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Angers

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2014

Primary Completion (Anticipated)

May 1, 2017

Study Registration Dates

First Submitted

September 8, 2015

First Submitted That Met QC Criteria

September 29, 2015

First Posted (Estimate)

September 30, 2015

Study Record Updates

Last Update Posted (Estimate)

September 30, 2015

Last Update Submitted That Met QC Criteria

September 29, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AOI 2013 - 11

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Huntington Disease

Clinical Trials on Eye-tracking

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe